The Administration Core will continue to be responsible for managerial oversight of all Johns Hopkins Breast Cancer SPORE Program activities. In addition the Administration Core will help facilitate interactions between Johns Hopkins Breast Cancer SPORE Program investigators and investigators associated with other Breast Cancer SPOREs. It will continue to assist in the orchestration of productive responses to new National Cancer Institute initiatives such as the NCI-Avon Progress for Patients Program. The structure of the Johns Hopkins Breast Cancer SPORE with its Principal Investigator, Research Project and Core Co- Leader Committee, Steering Committee, Institutional Advisory Board, and External Advisory Board has been designed to promote translational research by creating a breast cancer research culture that transcends academic departments, medical disciplines, and individual research skills. It provides high quality monitoring, evaluation, and oversight of all aspects of the Breast Cancer SPORE portfolio of Research Projects, Core Resources, Career Development Program, and Developmental Research Program and NCI Avon Progress for Patients Awards in a low-cost and efficient administrative structure. This highly experienced team facilitates all communications and meetings, meets all National Cancer Institute reporting requirements, maintains adherence to SPORE Program budget constraints and requirements, ensures compliance with NIH and Hopkins research guidelines, coordinates attendance of SPORE Program investigators at various SPORE-associated meetings, participates in SPORE Principal Investigators conference calls, and organizes responses to supplemental funding opportunities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA088843-09
Application #
7902239
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-30
Budget End
2010-09-29
Support Year
9
Fiscal Year
2009
Total Cost
$177,138
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Lo, Pang-Kuo (2018) FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells. Trends Diabetes Metab 1:
Cravero, Karen; Medford, Arielle; Pallavajjala, Aparna et al. (2018) Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity. Pract Lab Med 12:e00108
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Lo, Pang-Kuo (2017) The controversial role of forkhead box F2 (FOXF2) transcription factor in breast cancer. PRAS Open 1:
Haffner, Michael C; Esopi, David M; Chaux, Alcides et al. (2017) AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination. Nat Commun 8:142
Sunay, Melek M E; Foote, Jeremy B; Leatherman, James M et al. (2017) Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol 46:112-123
Parsons, Heather A; Beaver, Julia A; Cimino-Mathews, Ashley et al. (2017) Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 23:379-386
Cidado, Justin; Wong, Hong Yuen; Rosen, D Marc et al. (2016) Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 7:6281-93
Lo, Pang-Kuo; Lee, Ji Shin; Liang, Xiaohui et al. (2016) The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression. Cell Signal 28:1502-19

Showing the most recent 10 out of 282 publications